LGALS3 and metabolic dysfunction-associated steatohepatitis: Particularly, fibrotic NASH participants (18–75 years) were administered with the Galectin 3 inhibitors GR-MD-02 (8 mg/kg) [113] or GB1211 (10 and 100 mg/kg, orally, twice per day over 12 weeks) [114].